FDA Scrutiny Heightens on Gummy Supplement Label Claims; 48% Fail Vitamin C Purity
The US FDA is escalating oversight on gummy dietary supplements, driven by recent testing revealing significant label claim failures. Brand owners face increased compliance risk and potential market withdrawals.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Washington D.C., United States — 07 October 2026
The US Food and Drug Administration (FDA) is intensifying its focus on dietary supplement gummies, citing concerns over product integrity and label accuracy. This increased scrutiny follows findings that a substantial portion of functional gummies may not deliver their stated active ingredients. Natural product manufacturer NOW recently tested 25 vitamin C gummy supplements sold on Amazon, revealing a 48% failure rate. Only 13 products met their label claims, while 12 contained almost no detectable vitamin C. This data underscores persistent formulation and manufacturing challenges within the gummy sector.
Gummy production is inherently complex. Factors such as sugar content, heat stability of active ingredients, and potential foreign material contamination during processing contribute to the difficulty of maintaining ingredient potency and consistency. An FDA investigator previously highlighted these issues in May 2026, indicating a long-standing awareness within the agency regarding manufacturing hurdles specific to this format.
The burgeoning popularity of gummies, exemplified by companies like AG1 expanding into this category, is attracting greater regulatory attention. This market expansion, coupled with documented product failures, signals a tightening regulatory environment. Manufacturers and brand owners must address these formulation intricacies to ensure product stability, efficacy, and accurate labelling to avoid enforcement actions.
What this means for United States
US manufacturers and brand owners must immediately review and strengthen their Good Manufacturing Practices (GMPs) for gummy production, particularly regarding active ingredient stability and dosage accuracy. The reported 48% failure rate for vitamin C gummies on Amazon indicates a significant market vulnerability, demanding robust quality control from raw material to finished product. This will impact formulation costs and potentially increase lead times for compliant products. Brand owners should proactively conduct third-party testing to validate label claims, mitigating the risk of FDA warning letters and consumer litigation. Competitive positioning will increasingly favour brands demonstrating superior product integrity and transparency in a market under heightened regulatory microscope.
The FDA's focused attention signals a broader effort to ensure supplement quality across popular formats. Companies relying on gummies must prepare for more rigorous inspections and potential demands for substantiated claims, which will elevate compliance costs and necessitate reformulation for substandard products.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.